[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100523934":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":38,"collaborators":19,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":19,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":19,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":19,"overallStatus":63,"whyStopped":19,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Wedge resection","EXPERIMENTAL","Wedge resection is performed for early-stage lung cancer to remove a wedge-shaped section of lung tissue.",[13],"Procedure: Wedge resection",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","Wedge resection is a surgical procedure that is done to remove a wedge-shaped section of lung tissue, usually for treating lung cancer. A wedge resection is less invasive than some of the other surgical options used to remove lung cancer.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Tong Li","CONTACT","+86 18813039287","litong_medical@163.com",[27],{"facility":28,"status":19,"city":29,"state":19,"zip":19,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":19},"Fudan University Shanghai Cancer Center","Shanghai","China","CN",{"type":33,"coordinates":34},"Point",[35,36],121.45806,31.22222,{"lat":36,"lon":35},{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Haiquan Chen","Director in the Department of Thoracic Surgery, FUSCC","100523934","phase-3-wedge-resection-for-ground-glass-opacity-featured-lung-cancer-ectop-1020-100523934",false,"NCT06102161","Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)","Wedge Resection for Ground-glass Opacity-featured Lung Cancer With Size Less Than 2cm and Consolidation-to-tumor Ratio Between 0.25 to 0.5: a Single-arm, Multi-center, Prospective, Confirmatory Phase III Trial","Inclusion Criteria:\n\n1. Patients who sign the informed consent form and are willing to complete the study according to the plan;\n2. Aged from 18 to 80 years old;\n3. ECOG equals 0 or 1;\n4. Not receiving lung cancer surgery before;\n5. Intraoperative or postoperative pathologic diagnosis of lung adenocarcinoma;\n6. Single lung nodules with ground-glass dominant or pure ground-glass on CT, or multiple lung nodules with the major lesion being the aforementioned nodules;\n7. The nodule has a consolidation-to-tumor ratio (CTR) between 0.25 and 0.5 (including 0.25 and 0.5), and the nodule size is less than or equal to 2 cm;\n8. peripheral type of nodes, namely, nodes in the outer 1\u002F3 of the lung field.\n9. cT1N0M0 tumors;\n10. Complete tumor resection by wedge resection as assessed by the surgeon;\n11. Not receiving chemotherapy or radiotherapy before.\n\nExclusion Criteria:\n\n1. Postoperative pathologic diagnosis of adenocarcinoma in situ or minimally invasive adenocarcinoma.\n2. CTR is not between 0.25-0.5 or nodule size greater than 2 cm;\n3. Cannot be completely resected by wedge resection;\n4. Invasive lung adenocarcinoma or lung malignancy other than lung adenocarcinoma diagnosed cytologically or pathologically;\n5. Receiving lung cancer surgery before;\n6. Receiving radiotherapy or chemotherapy.","ALL","18 Years","80 Years",{"count":53,"type":54},286,"ESTIMATED","INTERVENTIONAL",[57],"PHASE3","This is a clinical trial from the Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1020. The goal of this clinical trial is to confirm the therapeutic effect of Wedge resection for ground-glass opacity-featured lung cancer with a size less than 2cm and a consolidation-to-tumor ratio between 0.25 to 0.5.",[60,61,62],"Lung Cancer","Wedge Resection","Ground-glass Opacity","NOT_YET_RECRUITING","2023-10-25",{"date":66,"type":67},"2023-10-26","ACTUAL",{"date":69,"type":54},"2023-11",{"date":71,"type":54},"2030-11",{"name":5,"class":6},1]